Pacer Advisors
VRDN icon

Pacer Advisors’s Viridian Therapeutics VRDN Stock Holding History

Pacer Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Buy
+1,816
New +$29.3K ﹤0.01% 2140
2024
Q3 		– Sell
-825
Closed -$10.7K – 2709
2024
Q2 		$10.7K Sell
825
-1,075
-57% -$14.9K ﹤0.01% 3537
2024
Q1 		$33.3K Buy
+1,900
New +$36.8K ﹤0.01% 3330

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pacer Advisors's VRDN Position: Q2 2026 in Review

Pacer Advisors opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 1,816 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in VRDN as recently as Q2 2024.

Pacer Advisors first reported a position in VRDN in Q1 2024 and has held it in 3 quarters since. The position peaked at $33.3K in Q1 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Pacer Advisors held 1,816 shares of Viridian Therapeutics worth $33K as of Q2 2026.
  • Viridian Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2140 holding.
  • Pacer Advisors first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Pacer Advisors's Viridian Therapeutics position peaked at $33.3K in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.